Accelerated Lymphocyte Reconstitution and Long-term Recovery After Transplantation of Lentiviral-transduced Rhesus CD34+ Cells Mobilized by G-CSF and Plerixafor
Overview
Authors
Affiliations
Objective: Granulocyte colony-stimulating factor (G-CSF) in combination with plerixafor produces significant mobilization of CD34(+) cells in rhesus macaques. We sought to evaluate whether these CD34(+) cells can stably reconstitute blood cells with lentiviral gene marking.
Materials And Methods: We performed hematopoietic stem cell transplantation using G-CSF and plerixafor-mobilized rhesus CD34(+) cells transduced with a lentiviral vector, and these data were compared with those of G-CSF and stem cell factor mobilization.
Results: G-CSF and plerixafor mobilization resulted in CD34(+) cell yields that were twofold higher than yields with G-CSF and stem cell factor. CD123 (interleukin-3 receptor) expression was greater in G-CSF and plerixafor-mobilized CD34(+) cells when compared to G-CSF alone. Animals transplanted with G-CSF and plerixafor-mobilized cells showed engraftment of all lineages, similar to animals who received G-CSF and stem cell factor-mobilized grafts. Lymphocyte engraftment was accelerated in animals receiving the G-CSF and plerixafor-mobilized CD34(+) cells. One animal in the G-CSF and plerixafor group developed cold agglutinin-associated skin rash during the first 3 months of rapid lymphocyte recovery. One year after transplantation, all animals had 2% to 10% transgene expression in all blood cell lineages.
Conclusions: G-CSF and plerixafor-mobilized CD34(+) cells accelerate lymphocyte engraftment and contain hematopoietic stem cell capable of reconstituting multilineage blood cells. These findings indicate important differences to consider in plerixafor-based hematopoietic stem cell mobilization protocols in rhesus macaques.
Uchida N, Li L, Nassehi T, Drysdale C, Yapundich M, Gamer J Cell Rep Med. 2021; 2(4):100247.
PMID: 33948577 PMC: 8080237. DOI: 10.1016/j.xcrm.2021.100247.
Stringaris K, Hoyt R, Davidson-Moncada J, Pantin J, Tisdale J, Uchida N Blood Adv. 2020; 4(24):6148-6156.
PMID: 33351110 PMC: 7757001. DOI: 10.1182/bloodadvances.2020003040.
Blum F, Hardy B, Bishop-Lilly K, Frey K, Hamilton T, Whitney J Sci Rep. 2020; 10(1):6387.
PMID: 32286417 PMC: 7156522. DOI: 10.1038/s41598-020-63196-0.
Sato N, Stringaris K, Davidson-Moncada J, Reger R, Adler S, Dunbar C Clin Cancer Res. 2020; 26(11):2573-2581.
PMID: 32034075 PMC: 7269806. DOI: 10.1158/1078-0432.CCR-19-2897.
Immunoresponse to Gene-Modified Hematopoietic Stem Cells.
Drysdale C, Tisdale J, Uchida N Mol Ther Methods Clin Dev. 2019; 16:42-49.
PMID: 31763350 PMC: 6859277. DOI: 10.1016/j.omtm.2019.10.010.